Top
Main
 
All Outcomes
 
RCT vs. Obs.
 
Feedback
Home
c19early.org COVID-19 treatment researchVitamin AVitamin A (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta
Home Adoption Other Treatments
@CovidAnalysis
Loading...
Analgesics⏵
Antiandrogens⏵
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle⏵
Melatonin
Metformin
Minerals⏵
Molnupiravir
Monoclonals⏵
Naso/orophar..⏵
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins⏵
More⏵

Supplementary Data — Vitamin A for COVID-19: real-time meta analysis of 20 studies (14 treatment studies and 6 sufficiency studies)

@CovidAnalysis, November 2024, Version 29V29
Post
Share
PDF
Studies
Feedback
https://c19early.org/vameta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Al-Sumiadai 86% 0.14 [0.03-0.61] death 2/70 14/70 Improvement, RR [CI] Treatment Control Al-Sumiadai 67% 0.33 [0.07-1.57] progression 2/50 6/50 Rohani (DB RCT) 26% 0.74 [0.31-1.76] hosp. 8/89 11/91 Rohani (DB RCT) 32% 0.68 [0.20-2.33] no recov. 4/89 6/91 Rohani (DB RCT) 80% 0.20 [0.05-0.91] no recov. 2/89 10/91 Rohani (DB RCT) 87% 0.13 [0.03-0.61] no recov. 1/89 8/91 Rohani (DB RCT) 49% 0.51 [0.13-1.98] no recov. 3/89 6/91 Rohani (DB RCT) 63% 0.37 [0.12-1.12] no recov. 4/89 11/91 Rohani (DB RCT) 20% 0.80 [0.31-2.04] no recov. 7/89 9/91 Rohani (DB RCT) 40% 0.60 [0.25-1.45] no recov. 7/89 12/91 Sarohan -282% 3.83 [1.58-9.24] death 9/10 4/17 Beigm.. (SB RCT) 89% 0.11 [0.01-1.98] death 0/30 4/30 ICU patients CT​1​ Beigm.. (SB RCT) 41% 0.59 [0.17-1.28] hosp. 4/30 16/30 ICU patients CT​1​ Beigm.. (SB RCT) 45% 0.55 [0.38-0.78] SOFA 30 (n) 30 (n) ICU patients CT​1​ Somi (RCT) -50% 1.50 [0.29-7.73] death 3/15 2/15 Somi (RCT) 0% 1.00 [0.24-4.18] ventilation 3/15 3/15 Somi (RCT) 25% 0.75 [0.20-2.79] ICU 3/15 4/15 Somi (RCT) -76% 1.76 [0.73-4.26] no improv. 15 (n) 15 (n) Somi (RCT) -8% 1.08 [0.87-1.34] hosp. time 15 (n) 15 (n) Doocy 26% 0.74 [0.11-4.80] death 1/8 23/136 Chung (RCT) 75% 0.25 [0.06-0.99] PASC 9 (n) 8 (n) LONG COVID Chung (RCT) 68% 0.32 [0.01-6.90] PASC 0/9 1/8 LONG COVID Chung (RCT) 70% 0.30 [0.04-2.31] PASC 1/9 3/8 LONG COVID Chung (RCT) 75% 0.25 [0.07-0.89] PASC 2/9 7/8 LONG COVID Taheri (DB RCT) 38% 0.62 [0.23-1.69] no recov. 5/30 8/30 post-COVID anosmia Taheri (DB RCT) 43% 0.57 [0.19-1.75] no recov. 4/30 7/30 post-COVID anosmia Taheri (DB RCT) 67% 0.33 [0.01-7.87] no recov. 0/30 1/30 post-COVID anosmia Taheri (DB RCT) 86% 0.14 [0.01-2.65] no recov. 0/30 3/30 post-COVID anosmia Taheri (DB RCT) 89% 0.11 [0.01-1.98] no recov. 0/30 4/30 post-COVID anosmia Taheri (DB RCT) 89% 0.11 [0.01-1.98] no recov. 0/30 4/30 post-COVID anosmia Al-Sumiadai 64% 0.36 [0.23-0.54] cases 20/97 65/112 COVIDENCE UK Holt 56% 0.44 [0.06-2.96] cases 1/91 445/15,136 Nimer 21% 0.79 [0.45-1.35] hosp. 15/144 204/2,004 Nimer 21% 0.79 [0.46-1.30] severe case 17/144 243/2,004 Vaisi 17% 0.83 [0.48-1.00] hosp. 1,140 (n) 2,815 (n) Vaisi 11% 0.89 [0.69-0.98] symp. case 1,140 (n) 2,815 (n) Wang 35% 0.65 [0.30-1.40] severe case n/a n/a Mendelian - per SD Wang 24% 0.76 [0.46-1.25] hosp. n/a n/a Mendelian - per SD Wang 31% 0.69 [0.53-0.90] cases n/a n/a Mendelian - per SD Vitamin A COVID-19 outcomes c19early.org November 2024 ​1​ CT: study uses combined treatment Favors vitamin A Favors control
Figure S1. All outcomes.
Loading..
Figure S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit    
Post
Share
@CovidAnalysis
FAQ
Public domain CC0 1.0